Congress Materials

Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
SelectI am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
I am a U.S. Patient / CaregiverNo, go back to the patient portal
SelectI am a U.S. Patient / CaregiverNo, go back to the patient portal
Non-US residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Poster
Law E, Sherif B, Williams N, Mitra D, Neary M, Nelson L, Harries M September 10, 2022 EADV 2022 Alopecia

Improvements in Patient-Reported Outcomes Based on Scalp Hair Regrowth Among Patients With Alopecia Areata: Analysis of the ALLEGRO 2b/3 Trial

View Presentation
Oral Presentation
Sinclair R, Lesiak A, Mehlis S, Kinoshita-Ise M, Arenberger P, Tsianakas A, Tziotzios C, Zhang F, Law EH, Lejeune A, Wolk R, Woodworth D September 10, 2022 EADV 2022 Alopecia

Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata: interim results from the ALLEGRO-LT phase 3, open-label study

View Presentation
Oral Presentation
Danby S, Matcher S, Byers R, Taylor R, Sahib S, Andrew P, Brown K, Kay L, Wright C, Pinnock A, Chittock J, Cha A, Adiri R, Zang C, Werth J, Cork M September 10, 2022 EADV 2022 Atopic Dermatitis

Novel non-invasive skin biomarkers discriminate topical anti-inflammatory treatments based on their potential for local adverse effects

View Presentation
Poster
Di J, Christakis Y, Mamashli F, Kelekar A, Bruno J, Zhang Y, Northcott C September 10, 2022 EADV 2022 Atopic Dermatitis

One scratch at a time: Nocturnal Scratch and Sleep improvements in Atopic Dermatitis with Abrocitinib

View Presentation
Poster
Feldman S, Thyssen J, Boeri M, Gerber R, Neary M, Cha A, Hauber B, Cappelleri J, Xenakis J, Leach C, Zeichner J September 10, 2022 EADV 2022 Atopic Dermatitis

Preferences for Topical Treatments in Patients With Mild-to-Moderate Atopic Dermatitis

View Presentation
Poster
Anderson P, Piercy J, Marwaha S, Lukic T, Lejeune A, Neary MP September 10, 2022 EADV 2022 Vitiligo

Real-World Treatment Patterns and Clinical Outcomes for Patients with Non-Segmental Vitiligo in the United States and Europe

View Presentation
Poster
Simpson E, Silverberg J, Nosbaum A, Winthrop K, Guttman-Yassky E, Hoffmeister K, Egeberg A, Valdez H, Fan H, Farooqui S, Chan G, Alderfer J, Romero W, Johnson S September 10, 2022 EADV 2022 Atopic Dermatitis

Safety of Abrocitinib in 3582 Patients With Moderate-to-Severe Atopic Dermatitis With Over 900 Patients Exposed for Almost 2 Years

View Presentation
Oral Presentation
Ferguson J, Eleftheriadou V, Nesnas J September 10, 2022 EADV 2022 Vitiligo

Vitiligo is associated with a reduction in incidence of melanoma and non-melanoma skin cancer: UK population-based cohort study

View Presentation